Advancements in NK Vaccines for Solid Tumors: A Focus on Ongoing Clinical Trials
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 28 February 2026 | Viewed by 246
Special Issue Editor
Interests: immunology; urology; bladder; prostate; bioinformatics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer immunotherapy has experienced significant advancements in developing natural killer (NK) cell-based vaccines for treating solid tumors. These vaccines utilize the power of the innate immune system to target and eliminate cancer cells, offering a promising option for patients with limited treatment alternatives.
We are excited to announce an upcoming Special Issue dedicated to exploring the latest breakthroughs in NK vaccine research, specifically focusing on their application in solid tumors. We invite original research articles, comprehensive reviews, and expert opinions that examine these innovative treatments' mechanisms of action, efficacy, and safety profiles.
Topics of interest include, but are not limited to:
- Preclinical studies demonstrate NK vaccines' antitumor effects against various solid tumors.
- Updates on the current status of ongoing clinical trials, including phase I, II, and III studies.
- Comparative analyses of different NK vaccine platforms and their performance in clinical settings.
- Strategies to enhance the efficacy of NK vaccines through combination therapies.
- Challenges in manufacturing and scaling NK vaccines for widespread clinical use.
- Insights into the immune response modulation by NK vaccines and their impact on long-term patient outcomes.
Our goal is to provide a comprehensive overview of the progress in this rapidly evolving field, highlighting the potential of NK vaccines to transform the landscape of solid tumor treatment.
Dr. Yutao Wang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- natural killer (NK) cell-based vaccines
- solid tumors
- cancer immunotherapy
- clinical trials
- immune response modulation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
